AAPL334.51+2.24 (+0.67%) ▲|ABBV261.68+4.56 (+1.77%) ▲|ABT102.73+0.78 (+0.77%) ▲|ACN194.40+10.50 (+5.71%) ▲|ADBE263.56+11.33 (+4.49%) ▲|AMAT426.19-30.30 (-6.64%) ▼|AMD495.42-20.71 (-4.01%) ▼|AMGN380.80+3.45 (+0.91%) ▲|AMT177.21-0.65 (-0.36%) ▼|AMZN253.96-2.82 (-1.10%) ▼|AVGO344.37-17.63 (-4.87%) ▼|AXP327.64+2.95 (+0.91%) ▲|BA209.92-0.54 (-0.25%) ▼|BAC59.40-3.30 (-5.26%) ▼|BKNG175.50+1.58 (+0.91%) ▲|BLK1,066.15-13.50 (-1.25%) ▼|BMY64.04+0.40 (+0.63%) ▲|BNY157.59-5.07 (-3.12%) ▼|BRK-B515.18+4.81 (+0.94%) ▲|C137.11-1.71 (-1.23%) ▼|CAT784.88-33.69 (-4.12%) ▼|CL88.27+1.47 (+1.69%) ▲|CMCSA24.89-0.32 (-1.25%) ▼|COF207.02-1.29 (-0.62%) ▼|COP136.34-1.01 (-0.74%) ▼|COST920.04+15.27 (+1.69%) ▲|CRM259.43+11.71 (+4.73%) ▲|CSCO110.31-1.82 (-1.62%) ▼|CVS95.76+1.10 (+1.16%) ▲|CVX211.80-2.26 (-1.06%) ▼|DE680.83+5.09 (+0.75%) ▲|DHR202.76+2.62 (+1.31%) ▲|DIS108.79+2.24 (+2.10%) ▲|DUK118.88-0.54 (-0.45%) ▼|EMR148.27-3.92 (-2.58%) ▼|FDX312.06+1.29 (+0.42%) ▲|GD357.32+1.42 (+0.40%) ▲|GE317.53-6.13 (-1.89%) ▼|GEV873.21-84.06 (-8.78%) ▼|GILD146.23+2.51 (+1.75%) ▲|GM87.09+1.47 (+1.72%) ▲|GOOG344.74+9.29 (+2.77%) ▲|GOOGL348.22+9.72 (+2.87%) ▲|GS989.32-39.86 (-3.87%) ▼|HD311.65+2.91 (+0.94%) ▲|HON201.22-1.15 (-0.57%) ▼|IBM249.31+6.02 (+2.47%) ▲|INTC97.54-5.41 (-5.25%) ▼|INTU339.28+17.71 (+5.51%) ▲|ISRG378.26+9.11 (+2.47%) ▲|JNJ267.06+1.48 (+0.56%) ▲|JPM350.09-6.14 (-1.72%) ▼|KO89.24+0.95 (+1.07%) ▲|LIN463.08-3.14 (-0.67%) ▼|LLY1,138.90+23.20 (+2.08%) ▲|LMT530.83+6.64 (+1.27%) ▲|LOW198.79+1.97 (+1.00%) ▲|LRCX274.88-23.34 (-7.83%) ▼|MA572.51+3.32 (+0.58%) ▲|MCD257.40+4.87 (+1.93%) ▲|MDLZ62.31-0.14 (-0.22%) ▼|MDT93.74+2.78 (+3.05%) ▲|META666.95+18.92 (+2.92%) ▲|MMM162.12-2.85 (-1.73%) ▼|MO70.60+1.62 (+2.34%) ▲|MRK144.64+0.71 (+0.49%) ▲|MS207.34-7.05 (-3.29%) ▼|MSFT507.36+11.73 (+2.37%) ▲|MU927.33-47.93 (-4.91%) ▼|NEE81.77-0.54 (-0.66%) ▼|NFLX80.41+3.01 (+3.89%) ▲|NKE37.05+0.25 (+0.68%) ▲|NOW142.45+9.92 (+7.48%) ▲|NVDA211.77-6.52 (-2.99%) ▼|ORCL143.52-6.77 (-4.50%) ▼|PEP136.41+0.09 (+0.07%) ▲|PFE27.74+0.02 (+0.07%) ▲|PG146.09+0.82 (+0.56%) ▲|PLTR173.86+6.63 (+3.96%) ▲|PM194.39+3.33 (+1.74%) ▲|QCOM180.40-1.57 (-0.86%) ▼|RTX195.05-2.64 (-1.33%) ▼|SBUX99.12+0.38 (+0.38%) ▲|SCHW107.25+0.00 (+0.00%) ▲|SO86.77-0.40 (-0.46%) ▼|SPG204.77-0.06 (-0.03%) ▼|T26.57+0.51 (+1.94%) ▲|TMO611.41+1.59 (+0.26%) ▲|TMUS182.41+0.08 (+0.04%) ▲|TSLA360.37-5.07 (-1.39%) ▼|TXN263.76-4.95 (-1.84%) ▼|UBER72.57+0.90 (+1.25%) ▲|UNH383.76+6.99 (+1.86%) ▲|UNP284.89+0.49 (+0.17%) ▲|UPS102.33+2.05 (+2.04%) ▲|USB62.62-0.23 (-0.36%) ▼|V374.27+3.82 (+1.03%) ▲|VZ51.33+0.72 (+1.43%) ▲|WFC88.60-1.69 (-1.87%) ▼|WMT109.53+2.38 (+2.22%) ▲|XOM164.53-1.46 (-0.88%) ▼|AAPL334.51+2.24 (+0.67%) ▲|ABBV261.68+4.56 (+1.77%) ▲|ABT102.73+0.78 (+0.77%) ▲|ACN194.40+10.50 (+5.71%) ▲|ADBE263.56+11.33 (+4.49%) ▲|AMAT426.19-30.30 (-6.64%) ▼|AMD495.42-20.71 (-4.01%) ▼|AMGN380.80+3.45 (+0.91%) ▲|AMT177.21-0.65 (-0.36%) ▼|AMZN253.96-2.82 (-1.10%) ▼|AVGO344.37-17.63 (-4.87%) ▼|AXP327.64+2.95 (+0.91%) ▲|BA209.92-0.54 (-0.25%) ▼|BAC59.40-3.30 (-5.26%) ▼|BKNG175.50+1.58 (+0.91%) ▲|BLK1,066.15-13.50 (-1.25%) ▼|BMY64.04+0.40 (+0.63%) ▲|BNY157.59-5.07 (-3.12%) ▼|BRK-B515.18+4.81 (+0.94%) ▲|C137.11-1.71 (-1.23%) ▼|CAT784.88-33.69 (-4.12%) ▼|CL88.27+1.47 (+1.69%) ▲|CMCSA24.89-0.32 (-1.25%) ▼|COF207.02-1.29 (-0.62%) ▼|COP136.34-1.01 (-0.74%) ▼|COST920.04+15.27 (+1.69%) ▲|CRM259.43+11.71 (+4.73%) ▲|CSCO110.31-1.82 (-1.62%) ▼|CVS95.76+1.10 (+1.16%) ▲|CVX211.80-2.26 (-1.06%) ▼|DE680.83+5.09 (+0.75%) ▲|DHR202.76+2.62 (+1.31%) ▲|DIS108.79+2.24 (+2.10%) ▲|DUK118.88-0.54 (-0.45%) ▼|EMR148.27-3.92 (-2.58%) ▼|FDX312.06+1.29 (+0.42%) ▲|GD357.32+1.42 (+0.40%) ▲|GE317.53-6.13 (-1.89%) ▼|GEV873.21-84.06 (-8.78%) ▼|GILD146.23+2.51 (+1.75%) ▲|GM87.09+1.47 (+1.72%) ▲|GOOG344.74+9.29 (+2.77%) ▲|GOOGL348.22+9.72 (+2.87%) ▲|GS989.32-39.86 (-3.87%) ▼|HD311.65+2.91 (+0.94%) ▲|HON201.22-1.15 (-0.57%) ▼|IBM249.31+6.02 (+2.47%) ▲|INTC97.54-5.41 (-5.25%) ▼|INTU339.28+17.71 (+5.51%) ▲|ISRG378.26+9.11 (+2.47%) ▲|JNJ267.06+1.48 (+0.56%) ▲|JPM350.09-6.14 (-1.72%) ▼|KO89.24+0.95 (+1.07%) ▲|LIN463.08-3.14 (-0.67%) ▼|LLY1,138.90+23.20 (+2.08%) ▲|LMT530.83+6.64 (+1.27%) ▲|LOW198.79+1.97 (+1.00%) ▲|LRCX274.88-23.34 (-7.83%) ▼|MA572.51+3.32 (+0.58%) ▲|MCD257.40+4.87 (+1.93%) ▲|MDLZ62.31-0.14 (-0.22%) ▼|MDT93.74+2.78 (+3.05%) ▲|META666.95+18.92 (+2.92%) ▲|MMM162.12-2.85 (-1.73%) ▼|MO70.60+1.62 (+2.34%) ▲|MRK144.64+0.71 (+0.49%) ▲|MS207.34-7.05 (-3.29%) ▼|MSFT507.36+11.73 (+2.37%) ▲|MU927.33-47.93 (-4.91%) ▼|NEE81.77-0.54 (-0.66%) ▼|NFLX80.41+3.01 (+3.89%) ▲|NKE37.05+0.25 (+0.68%) ▲|NOW142.45+9.92 (+7.48%) ▲|NVDA211.77-6.52 (-2.99%) ▼|ORCL143.52-6.77 (-4.50%) ▼|PEP136.41+0.09 (+0.07%) ▲|PFE27.74+0.02 (+0.07%) ▲|PG146.09+0.82 (+0.56%) ▲|PLTR173.86+6.63 (+3.96%) ▲|PM194.39+3.33 (+1.74%) ▲|QCOM180.40-1.57 (-0.86%) ▼|RTX195.05-2.64 (-1.33%) ▼|SBUX99.12+0.38 (+0.38%) ▲|SCHW107.25+0.00 (+0.00%) ▲|SO86.77-0.40 (-0.46%) ▼|SPG204.77-0.06 (-0.03%) ▼|T26.57+0.51 (+1.94%) ▲|TMO611.41+1.59 (+0.26%) ▲|TMUS182.41+0.08 (+0.04%) ▲|TSLA360.37-5.07 (-1.39%) ▼|TXN263.76-4.95 (-1.84%) ▼|UBER72.57+0.90 (+1.25%) ▲|UNH383.76+6.99 (+1.86%) ▲|UNP284.89+0.49 (+0.17%) ▲|UPS102.33+2.05 (+2.04%) ▲|USB62.62-0.23 (-0.36%) ▼|V374.27+3.82 (+1.03%) ▲|VZ51.33+0.72 (+1.43%) ▲|WFC88.60-1.69 (-1.87%) ▼|WMT109.53+2.38 (+2.22%) ▲|XOM164.53-1.46 (-0.88%) ▼|
23.9 C
New York
Monday, September 14, 2026

Tag: collaboration

Autoimmune Collaboration and Licensing Deals Report 2025: Comprehensive Analysis of 943 Autoimmune Licensing Deals (2016-2025) Across 30+ Diseases

The 2025 report on Autoimmune Collaboration & Licensing Deals analyzes 943 agreements from 2016-2025, covering over 30 diseases including MS, RA, lupus, and Crohn’s. Access deal terms, financials, and SEC contracts for top biopharma partnerships. A must-have for benchmarking, due diligence, and strategic planning in autoimmune R&D and commercialization.
The 2025 report on Autoimmune Collaboration & Licensing Deals analyzes 943 agreements from 2016-2025, covering over 30 diseases including MS, RA, lupus, and Crohn’s. Access deal terms, financials, and SEC contracts for top biopharma partnerships. A must-have for benchmarking, due diligence, and strategic planning in autoimmune R&D and commercialization.

Astronergy reaches first global ASTRO N8 order with GES Siemsa

SHANGHAI, June 12, 2025 /PRNewswire/ -- At SNEC 2025, one of the world's most influential solar industry exhibitions, Astronergy officially signed a landmark cooperation agreement...

NetDragon Advances Its ESG Commitment: Flagship IP Eudemons Launches Cross-Sector Campaign to Protect Asian Elephants, Ushering in a New Chapter of “Gaming + Philanthropy”

HONG KONG, June 12, 2025 /PRNewswire/ -- NetDragon Websoft Holdings Limited ("NetDragon" or the "Company"; Hong Kong Stock Code: 777), a global leader in...

Final Call for Entries: Submission Deadline Nears for the Seoul Design Award 2025

SEOUL, South Korea, June 12, 2025 /PRNewswire/ -- The Seoul Design Foundation announces that the submission period for the Seoul Design Award 2025 is...

LONGi Officially Launches HIBC Technology and True 700W module on the SNEC2025

SHANGHAI, June 12, 2025 /CNW/ -- On June 11, LONGi officially released its newly developed HIBC technology and mass-produced module products at the 18th (2025) International...

Anna Ridler and Sofia Crespo win the Artists of the Year category of the Arab Bank Switzerland’s Digital Art Prize 2025

The ABS Digital Art Prize was founded in 2023 as the first award by a major institution to recognize and celebrate on-chain digital artists.Artist of...

Ericsson and Google Cloud team up to deliver carrier-grade 5G core as-a-service built with AI at the foundation

Ericsson On-Demand delivers a significant shift in how core network services are deployed, managed and scaledProvisions core services in minutes, allowing Communication Service Providers...

Aquaporin appoints Chief Executive Officer

Company announcementNo. 09/2025 Inside information Aquaporin A/SNymøllevej 78DK-2800 Kongens Lyngbyaquaporin.comCompany registration no.: DK28315694 KONGENS LYNGBY, Denmark, June 12, 2025 /PRNewswire/ -- The Board of Directors of Aquaporin...

Primax-Tymphany Group Joins Microsoft Device Ecosystem Platform (MDEP) to Enhance Conferencing Technology

TAIPEI, June 12, 2025 /PRNewswire/ -- The Primax-Tymphany Group, a global leader in conferencing technology, is committed to delivering secure, flexible, and user-friendly conferencing products...

Greater Than and Smart Eye Deepen Collaboration with Predictive Risk Scoring in Upgraded Driver Support System

Greater Than's AI-generated risk intelligence now integrated in Smart Eye's new version AIS system Predicts crashes in advance, improving risk management for fleet and transport...

NXP and Rimac Technology Co-Develop Centralized Vehicle Architecture for Advanced Domain and Zonal Control

EINDHOVEN, The Netherlands, June 12, 2025 (GLOBE NEWSWIRE) -- NXP Semiconductors N.V. (NASDAQ: NXPI), the worldwide leader in automotive processing, today announced its collaboration with Rimac Technology, a leading automotive industry supplier specialized in high-performance control systems, to advance centralized architectures for SDVs. The jointly developed solution features NXP’s S32E2 processors, which are part of NXP's comprehensive S32 Automotive Processing Platform, designed for current and future connectivity, security and safety challenges in automotive. The S32E addresses the vehicle’s need for high-performance deterministic real-time domain and zonal control in a multi-applications environment.

GCL SI Joins TianGong Initiative as the First Solar PV Company, Pioneering Carbon Transparency in Supply Chains

SHANGHAI, June 12, 2025 /PRNewswire/ -- On the opening day of the 2025 SNEC PV Power Expo, GCL System Integration Technology Co., Ltd. ("GCL SI")...

NIRA Dynamics Strengthens Automotive Safety Through Strategic Partnership with BANF Intelligent Tire System

Strategic Partnership Enhances Safety and Efficiency in Trucking SAN FRANCISCO, June 12, 2025 /PRNewswire/ -- Swedish automotive software leader NIRA Dynamics AB is taking vehicle safety...

Real-world prospective data confirms improved risk stratification in multiple myeloma using SKY92 gene expression profiling

According to clinical guidelines, high-risk myeloma patients should receive intensified treatment regimens. However, heterogeneity in clinical markers and staging systems lead to various interpretations of...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsCollaboration